“
TL;DR
The central objective was to evaluate the association between pretreatment skeletal muscle mass index (SMI) and long-term survival.
PLOS ONE · 7 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central objective was to evaluate the association between pretreatment skeletal muscle mass index (SMI) and long-term survival.
The central objective was to evaluate the association between pretreatment skeletal muscle mass index (SMI) and long-term survival. The analysis found that a lower pretreatment SMI was significantly associated with poorer overall survival (OS; HR = 1.56) and cancer-specific survival (CSS; HR = 1.75). The authors conclude that pretreatment SMI may serve as a reliable prognostic indicator. Key limitations include the retrospective nature of all included studies, relatively small sample sizes, and the inability to perform subgroup analyses for factors like TNM stage and age due to missing data. The authors state that prospective studies are needed to verify these findings.